SeaStar Medical Holding Corporation is expected to report Q2 2026 revenue of $0.49 million and a consensus EPS loss of $0.97, with its stock currently trading near $3.28 against an average analyst price target of $8.00. Investors are primarily focused on the commercial traction and initial revenue growth from Quelimmune, the company’s first FDA-approved therapy for pediatric acute kidney injury.
This quarter marks a critical transition as SeaStar ramps up its commercial infrastructure and expands its SAVE Registry post-approval. Additionally, stakeholders are looking for enrollment updates on the pivotal NEUTRALIZE-AKI trial in adults, which represents the company's largest market opportunity for its selective cytopheretic device technology.